Leflutrozole

Leflutrozole

Clinical data
Other names	BGS-649; CGP-47645
Routes of administration	By mouth
Identifiers
IUPAC name 4-[(4-Cyanophenyl)-fluoro-(1,2,4-triazol-1-yl)methyl]benzonitrile
CAS Number	143030-47-1
PubChem CID	126735
ChemSpider	112569
UNII	RCX0IE6EJZ
ChEMBL	ChEMBL225550
CompTox Dashboard (EPA)	DTXSID80162296
Chemical and physical data
Formula	C17H10FN5
Molar mass	303.300 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)(N3C=NC=N3)F
InChI InChI=1S/C17H10FN5/c18-17(23-12-21-11-22-23,15-5-1-13(9-19)2-6-15)16-7-3-14(10-20)4-8-16/h1-8,11-12H Key:PZDLRBUQYWMNBR-UHFFFAOYSA-N

Leflutrozole (developmental code names BGS-649, CGP-47645) is an aromatase inhibitor which is under development by Mereo BioPharma and Novartis for the treatment of hypogonadism in men. It was also under investigation for the treatment of endometriosis, but development for this indication was discontinued. As of December 2017, leflutrozole is in phase II clinical trials for hypogonadism.

See also

• List of investigational sex-hormonal agents § Estrogenics

External links

• Leflutrozole - AdisInsight